Cargando…

Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study

BACKGROUND: Although many studies have reported the predictors of fractures in patients with rheumatoid arthritis (RA) who are not receiving anti-osteoporotic treatments or who are receiving unspecified treatments, studies focusing on the predictors of fracture in patients with RA who are currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishimoto, Yuji, Kato, Yoshihiro, Uemura, Manami, Kuranobu, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883631/ https://www.ncbi.nlm.nih.gov/pubmed/35220965 http://dx.doi.org/10.1186/s41927-021-00243-x

Ejemplares similares

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis
por: Meinen, Rahel, et al.
Publicado: (2016)

Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies
por: Mori, Yu, et al.
Publicado: (2021)

Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates
por: Iwamoto, Jun, et al.
Publicado: (2014)

Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy
por: Aeberli, Daniel, et al.
Publicado: (2013)

Oral bisphosphonate use and lung cancer incidence among postmenopausal women
por: Tao, M H, et al.
Publicado: (2018)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
por: Park, Ji-Heh, et al.
Publicado: (2017)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis
por: Bastounis, A., et al.
Publicado: (2022)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007
por: Wang, Zhong, et al.
Publicado: (2011)

Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility
por: Lambert, Anne-Sophie, et al.
Publicado: (2017)

Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws
por: Conte-Neto, Nicolau, et al.
Publicado: (2012)

Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus
por: Park, Eun-Young, et al.
Publicado: (2018)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020)

Risk factor analysis of fragility fractures in rheumatoid arthritis: A 3-year longitudinal, real-world, observational, cohort study
por: Lin, Po-Heng, et al.
Publicado: (2021)

Predictors of fatigue in rheumatoid arthritis
por: Druce, Katie L, et al.
Publicado: (2019)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
por: Dieckmeyer, Michael, et al.
Publicado: (2019)

Understanding fragility fracture patients’ decision-making process regarding bisphosphonate treatment
por: Wozniak, L. A., et al.
Publicado: (2016)

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates
por: Abelson, A., et al.
Publicado: (2009)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Predictors of diastolic dysfunction in rheumatoid arthritis
por: Sakthiswary, Rajalingham, et al.
Publicado: (2015)

Vitamin Status as Predictors in Rheumatoid Arthritis
por: MITITELU, RADU RAZVAN, et al.
Publicado: (2021)

Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study
por: Zampeli, Evangelia, et al.
Publicado: (2012)

The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis
por: Brand, Caroline, et al.
Publicado: (2008)

Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports
por: Conte-Neto, Nicolau, et al.
Publicado: (2011)

Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates
por: Baroja-Mazo, Alberto, et al.
Publicado: (2012)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
por: Marozik, Pavel, et al.
Publicado: (2019)

Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses
por: Bastounis, Anastasios, et al.
Publicado: (2022)

Establishment of a preliminary FRAX®-based intervention threshold for rheumatoid arthritis–associated fragility fracture: a 3-year longitudinal, observational, cohort study
por: Yu, Shan-Fu, et al.
Publicado: (2022)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rmu9muv0mvsh0tueqhgh4e14tm